Clinical Edge Journal Scan

Residual inflammation may persist despite stable minimal disease activity in PsA


 

Key clinical point: Ultrasound-detected residual inflammation in peripheral articular structures may be present even in patients with psoriatic arthritis (PsA) who have achieved stable minimal disease activity (MDA), with residual inflammation being more prevalent in patients with shorter duration of MDA.

Major finding: Despite stable MDA, 54.2% of patients had 1 positive Power Doppler (PD) signal in examined tissues, with 19.4% and 23.6% of patients showing 1 joint and enthesis with a positive PD signal, respectively. A higher proportion of patients with 12 vs >12 months of sustained MDA had 1 ultrasound detected PD lesion (55% vs 41%; P = .024).

Study details: This cross-sectional study included 72 patients with PsA who were on biologic or conventional synthetic disease-modifying antirheumatic drugs for 12 months and in continuous MDA for ≥6 months.

Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.

Source: Macchioni P et al. Residual inflammation in psoriatic arthritis patients in stable minimal disease activity. Front Med. 2022;9:1096547 (Dec 20). Doi: 10.3389/fmed.2022.1096547

Recommended Reading

FDA approves Idacio as eighth adalimumab biosimilar in U.S.
Psoriatic Arthritis ICYMI
FDA will review pediatric indication for roflumilast cream
Psoriatic Arthritis ICYMI
Cardiovascular risk score multipliers suggested for rheumatic diseases
Psoriatic Arthritis ICYMI
Commentary: Bimekizumab, and PsA's Relationships With AS and Crohn's Disease, January 2023
Psoriatic Arthritis ICYMI
Topical psoriasis treatments
Psoriatic Arthritis ICYMI
Teamwork guides cardio-rheumatology clinics that care for unique patient population
Psoriatic Arthritis ICYMI
Psoriasis, psoriatic arthritis show distinctive skin microbiomes
Psoriatic Arthritis ICYMI
No benefits of concomitant methotrexate in PsA patients treated with ustekinumab
Psoriatic Arthritis ICYMI
Early achievement of minimal disease activity important for long-term benefits in PsA
Psoriatic Arthritis ICYMI
TNFi and increased hematologic malignancy risk in PsA: Is there a link?
Psoriatic Arthritis ICYMI